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ABSTRACT 
Autoimmune hepatitis (AIH) is a corticosteroid responsive, autoimmune liver disease 
arising consequent to immunogenetic and environmental risk factors. The clinical 
course reflects relapsing and remitting, hepatocyte targeted, immunologic damage, 
countered by reparative responses to cell injury. Appropriate and timely 
immunosuppressive therapy drives disease into remission, albeit accompanied by 
inevitable side effects. Many challenges faced in the clinic reflect practice that must 
capture a heterogeneous disease presentation, course, and treatment response, as well 
as treatment tolerability. In this grand round we appraise the evidence supporting 
currently applied treatment approaches, address the impact of autoimmune liver 
disease ‘crossover or overlap’ presentations, explore important clinical correlates to 
immune-serological classifiers, and discuss the factors influencing choice of 
alternative therapy in difficult-to-treat situations. 
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Vignette  
A 19-year old woman (body mass index [BMI] 45.6 kg/m2) presented with a 6-week 
history of malaise, nausea and progressive jaundice, without features of liver 
decompensation. Serum tests showed an alanine transaminase (ALT) of 592 IU/L 
(upper limit of normal [ULN] 40 IU/L), bilirubin of 426 µmol/L (ULN 21 µmol/L), 
serum IgG 20.89 g/L (ULN 16.10 g/L), and seropositivity for anti-nuclear antibodies 
(ANA; titre 1:100; homogeneous) and anti-smooth muscle antibodies (ASMA). An 
extended viral screen was negative (hepatitis A, B, C and E; Epstein Barr Virus; 
Human Immunodeficiency Virus and Cytomegalovirus). Liver biopsy showed 
features of acute lobular hepatitis compatible with acute autoimmune hepatitis (AIH). 
There was moderately severe inflammatory activity including foci of bridging 
necrosis. No steatosis was evident. On starting oral Prednisolone (20mg daily; 
0.25mg/kg/d), biochemical and immunological remission resulted within 1 month 
(Figure 1A). Azathioprine was introduced (when bilirubin <100 µmol/L) alongside 
gradual tapering in Prednisolone. 
 
The patient sustained biochemical and immunological remission for a period of 16 
months on Azathioprine monotherapy, however she failed to attend clinic visits 
during the following year. The patient later represented with generalised fatigue, 
malaise, a markedly elevated serum ALT (628 IU/L, bilirubin 20 mol/L), and 
reported poor adherence to treatment over the past 10 months. Whilst remission could 
be induced with oral Prednisolone once again (20mg daily), maintenance proved 
difficult despite reintroduction of Azathioprine (2mg/kg/d). Ongoing biochemical and 
immunological activity was evident whenever Prednisolone dosage was tapered 
below 15mg/day, and Azathioprine metabolite monitoring revealed sub-therapeutic 6-
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thioguanine nucleotide values (178 pmol/8 x108 cells; normal range 235-450 pmol/8 
x108 cells). The patient was trialled on allopurinol (100mg daily) to counteract 
methylmercaptopurine shunting [1], but unfortunately developed significant side 
effects (nausea/abdominal pain – allopurinol stopped) and inflammatory indices 
remained abnormal (ALT 866 IU/L, bilirubin 20 µmol/L, IgG 37.64 g/L). Given the 
young presenting age and difficult to treat disease, a magnetic resonance 
cholangiogram (MRCP) was performed; however no features of primary sclerosing 
cholangitis were evident. 
 
Drug intolerance together with inability to attain therapeutic thiopurine metabolite 
values led to trial of alternative immunosuppression; first Mycophenolate mofetil 
(MMF; with appropriate counselling regarding contraception) and later Tacrolimus 
[2]. Ultimately however, the patient continued to manifest features of active hepatitis 
despite therapy, necessitating repeated courses of high-dosage Prednisolone (>30mg 
daily) to the point of developing Cushing’s syndrome with very difficult glycaemic 
control. An attempt to switch Prednisolone to Budesonide was also made [3,4]; 
however ongoing inflammatory activity persisted. A repeat liver biopsy obtained 5 
years after the initial presentation showed features of chronic hepatitis with moderate 
interface hepatitis and bridging fibrosis. There was also ongoing lobular 
inflammation, moderate in severity with foci of centrilobular necrosis. To this effect 
the patient received intravenous rituximab. This led to successful biochemical 
remission until the time of writing (approximately 12 months) and marked 
improvement in serum immunology (ALT 15 IU/L and IgG 17.93 g/L, respectively) 
(Figure 1B).  
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DISCUSSION 
The patient description raises pertinent clinical questions relevant to the optimal 
management of AIH: 
 
How to guide decision making in use of therapy?  
AIH is a persistent and relapsing immune-mediated liver injury characterised by 
(often chronic) hepatitis of varying severity, which carries significant risk of 
developing end-stage liver disease unless treated by timely and effective therapy. Our 
understanding of aetiological drivers is incomplete, but mixed environmental, genetic 
and epigenetic drivers of inflammation are all presumed relevant. For example strong 
HLA associations exist for disease risk, and non-HLA genetic variants (some rare but 
functional e.g. in the genes AIRE, GATA-2, CTLA-4, others common e.g. in the gene 
locus for SH2B3 but without clear-cut coding impact) have been identified. The 
paradigm of drug induced AIH, such as with Nitrofurantoin, as well as the 
identification of HLA as a strong risk factor in many drug induced liver injuries, 
supports how environmental triggers can precipitate immune injury. Furthermore, the 
insight that indeed other autoimmune diseases are not as frequent in family members 
as initially expected indicates the importance of environmental triggers. Ongoing 
research is focused on harnessing a better understanding of the ongoing subtle, but 
deleterious changes in immunoregulation that represent disease drivers, as well as 
therapeutic targets [5].  
 
Determining activity, severity and chronicity of disease 
Approaches to treatment derive from historic placebo-controlled trials, in which those 
with untreated moderate-severe AIH (AST >5xULN, globulins >2xULN, liver biopsy 
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showing confluent necrosis) had a very poor prognosis, with 5 and 10-year survival of 
50% and 10% respectively. Treated 10-year transplant-free survival rates, by contrast, 
approximate 90% [6–10], accepting however that intent is usually with regard to 
much longer term outcome.  
 
Current guidelines recommend liver biopsy at the time of first presentation [6,7]; 
which is a critical tool for identifying features that are supportive of diagnosis, 
determining disease severity (inflammatory activity and fibrosis stage), and 
discriminating acute vs. chronic presentations (Figure 1C and 1D). Classical 
histological findings of chronic AIH include lymphoplasmacytic infiltration, 
predominantly located in portal tracts and associated with varying degrees of interface 
hepatitis. Other typical features of AIH, although not universally present, are rosette 
formation, emperipolesis and plasma cell enrichment. Interface hepatitis is associated 
with the development of periportal fibrosis, which may progress to bridging fibrosis 
and ultimately lead to cirrhosis. By contrast, lobular inflammation predominates in 
patients with an acute presentation, in addition to typical hepatocyte ballooning, 
lobular disarray and spotty hepatocyte apoptosis/necrosis. More severe cases may be 
associated with extensive hepatocyte necrosis, ranging from confluent necrosis 
through bridging necrosis to panacinar or multiacinar necrosis (Figure 1D). The latter 
is typically seen in cases presenting with signs of acute liver failure. Similar changes 
can also be seen in cases of acute viral or drug-induced hepatitis. Features favouring 
AIH as a likely cause of acute hepatitis include prominent portal inflammation with 
interface hepatitis (resembling changes seen in chronic AIH), a plasma-cell rich 
inflammatory infiltrate, lymphoid aggregates and centrilobular accentuation of 
inflammation (central perivenulitis). Emperipolesis and hepatocyte rosettes are less 
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helpful in diagnosing AIH with an acute presentation as these changes are also 
frequently present in other causes of acute lobular hepatitis [11].  
 
The mononuclear infiltrate of AIH tends to be predominated by CD4+ T-cells that 
localise to the periportal areas with hepatocyte damage thought to include apoptosis 
induction and direct effects of the cytokines interferon-γ, tumour necrosis factor α and 
interleukin (IL)-17. Disease-specific increases of IL-17 in both the peripheral blood 
and liver are reported, and it is proposed that differentiation into Th17 as oppose to 
regulatory T-cell (Treg) phenotypes underlie the pro-inflammatory nature of immune-
mediated liver injury. CD8+ T-cells, by contrast to their CD4+ counterparts, more 
often localise to the areas of interface activity, and are overall less prevalent than in 
other causes of hepatitis. Nevertheless CD8+ T-cells are highly activated in AIH, 
demonstrating an upregulation of several cytotoxic molecules including granzyme B 
and perforin, and resistance to the anti-proliferative effects of Treg in vitro. Plasma 
cells, which develop from activated B-cells, are also numerous in AIH livers. The 
observed correlation between intra-portal B-cell numbers and serum IgG values, 
together with case series supporting efficacy of the B-cell depleting agent rituximab 
in AIH lend further support to their role in disease pathogenesis. This aligns with an 
increased understanding of the role B-cells play in regulating T-cell function (B-cell 
depletion favouring Treg function) [5]. 
 
High-risk disease 
At least one-third of adults have cirrhosis at diagnosis [8,9], conferring a heightened 
mortality risk and/or need for transplantation (hazard ratio 21.25) [9]. Offering 
treatment to avoid transplantation is deemed mandatory in all patients with advanced 
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fibrosis, and for those with established, compensated liver cirrhosis and persistent 
inflammatory activity [6,7]. By contrast, when patients present with overt hepatic 
decompensation, then the risk versus benefit is less apparent. If experience and 
expertise are not available locally, then immunosuppression should be administered 
only following discussion with a transplant unit and when inflammatory activity is 
overt histologically. 
 
The merits of immunosuppression for patients with inactive (“burned out”) cirrhosis 
are contentious, given that inflammatory activity (hepatitis) is prerequisite for 
diagnosis. In any event, the impact on overall outcome is generally thought to be very 
low for this subgroup, leaving just the risk of drug-related side effects [7]. It is 
therefore reasonable for the patient presenting with ‘burned out’ AIH to receive no 
direct immunosuppression, but they must still be monitored and surveyed.  
 
Acute-severe (AS)-AIH presentations, and in particular those with fulminant hepatic 
failure are additional groups who may not necessarily benefit from 
immunosuppression. AS-AIH is defined by an acute onset of symptoms to 
presentation of <26 weeks, associated with significant hepatic dysfunction (INR 
⩾1.5) that develops at any time during the index presentation, despite the absence of 
chronic disease features on liver histology [12]. Important in managing such patients 
is the careful attention to prevention and treatment of inter-current sepsis and 
management in the context of expectant transplantation. The short-term mortality 
approaches ~20%, with 60% of patients needing a liver transplant [12]. Thus it is 
advised that immunosuppression only be trialled in close liaison with a transplant 
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unit, whilst seeking early evidence of therapy response (e.g. falling bilirubin) or lack 
thereof. 
 
Mild disease 
The benefits of treatment in those classified as ‘asymptomatic’ are also debated. The 
10-year survival in this group is 80% based on historical data, therefore mirroring that 
of the overall AIH population. However an Italian group reported patients with 
asymptomatic disease (n=90) compared to symptomatic presentations (n=215) as 
exhibiting lower mean serum ALT values (7 vs. 23xULN), lower serum bilirubin (1.4 
vs. 8.6mg/dL) and milder histological disease activity (histological activity index 
[HAI]: 7 vs. 9). Nevertheless, development of cirrhosis (18.5% vs. 12.2%), and event-
free survival – defined as any episode of decompensation, hepatocellular carcinoma, 
listing for liver transplantation or death – developed at a similar rate in asymptomatic 
vs. symptomatic patients (22 vs. 24%) [13]. Furthermore, 25% of asymptomatic 
patients may go on to develop symptoms during follow-up with fluctuating 
histological inflammatory activity; and whilst improvement in biochemical indices 
may occur spontaneously, resolution of inflammation is less frequent in untreated 
patients (12% vs. 63%) [14]. These data indicate that an absence of symptoms must 
not be a factor determining whether or not to treat patients. In fact, data to support 
empirical treatment in this group stems from data in patients of older age, 25% of 
whom are asymptomatic yet more likely to be cirrhotic at presentation (odds ratio 
[OR]: 1.58) [15]. Elderly patients respond well to treatment, and relapse less 
commonly on treatment withdrawal compared to patients of younger age onset (OR: 
0.38) [15,16]. Equally, non-severe presentations with mild interface hepatitis and 
modest biochemical changes (normal serum bilirubin, serum transaminase values 
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<5xULN) may not necessarily follow a sedentary course, and mild AIH can be 
interspersed with phases of severe activity that can be aggressive.  
 
What constitutes effective therapy? 
Treatment goals need to be personalised; resolution of liver biochemistry can be 
achieved in ~75% of patients, of which ~80% also attain normal serum 
immunoglobulin values [9].  Between 39% to 65% of patients normalise serum ALT 
within six months of starting treatment (93% at 1 year) [3,8,16]. Failure to attain 
normal transaminases by 6-12 months confers an increased risk of liver 
transplantation / liver-related death (HR 4.8); whereas complete biochemical and 
immunological remission (serum transaminases, bilirubin and IgG values all <ULN) 
associates with reduced histological disease activity, regression of liver stiffness as 
assessed by transient elastography, and can predict histological fibrosis regression 
after a median of 5.5 years (range 1-9.7 yrs.; relative risk [RR]: 3.66) [17]. However 
histological improvement lags behind normalisation of laboratory values by at least 6-
12 months [10,18]; and failure to attain remission histologically despite doing so 
biochemically is associated with >2-fold increased risk of progression to 
transplantation and all-cause mortality [10].  
 
Inducing remission  
With good reason (efficacy) corticosteroids, either Prednisolone or Budesonide, are 
the mainstay for inducing remission in most patients. Corticosteroids alone or in 
combination with Azathioprine are considered equally effective, although an 
individualised approach is needed to ensure the best long-term outcomes for patients. 
Combination therapy can be instituted either at diagnosis, or quite reasonably with a 
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slight delay of 2-4 weeks in starting Azathioprine, which is without detriment to long-
term disease control.  
 
Many treatment algorithms have been proposed [6,7], but there is wide variation in 
practice, a reflection of disease heterogeneity but equally a lack of real-world 
consensus on the value of immunosuppression intensity to the individual patient 
(Table 1) [19]. A brief report from Hamburg suggested that high prednisolone 
dosages result in more rapid normalisation of serum transaminases [20], although 
whether they are universally necessary in view of side effects (and equally whether 
they confer better long term outcomes) is unclear; particularly given the heterogeneity 
in disease presentation and challenges in identifying at baseline patients most in need 
of ‘high-intensity’ immunosuppression. As the patient in our vignette shows, a severe 
presentation is not correlated with an absolute need for high dose Prednisolone to 
induce good disease control. Moreover there is widespread concern about weight gain 
and cosmetic impact, in addition to the burden of depressive symptoms, related 
treatment non-adherence, and reduced health-related quality of life associated with 
corticosteroids [21,22]. Important factors related to dose and corticosteroid choice 
must include the presence of obesity, metabolic bone disease, diabetes, hypertension 
or concern over cosmetic side effects of Prednisolone, as well as clinician concern for 
adherence. Budesonide has higher affinity for the glucocorticoid receptor than 
Prednisolone but undergoes over 90% hepatic first pass metabolism, the resulting 
catabolites being devoid of glucocorticoid activity thus limiting corticosteroid related 
side effects. Despite improved tolerability with Budesonide, advanced liver disease or 
porto-systemic shunts pose a risk for corticosteroid-induced side effects as a result of 
altered hepatic clearance and increased systemic availability. For this reason the 
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labelled indication excludes individuals with cirrhosis. In the context of severe 
presentations of AIH, or as switch-over therapy for side effects, more efficacy data is 
needed [4].  
 
Azathioprine monotherapy is largely inappropriate for inducing remission, given its 
slow onset of action and poorer patient outcomes when monotherapy is compared to 
Prednisolone alone or Prednisolone/Azathioprine in combination [23]. However there 
are very occasional patients with mild disease activity, no liver fibrosis, and good 
clinical or personal reasons to avoid corticosteroids, in whom monotherapy with 
azathioprine from the outset, with equivalent treatment goals, can be rarely 
considered. 
 
Maintaining remission  
In most, corticosteroids are combined (once an initial response is confirmed) with 
long-acting immunomodulators during the induction phase [19]. Whilst drug-induced 
hepatotoxicity is uncommon, phased introduction of Azathioprine is pragmatically 
helpful in managing and traversing the side effects of treatment. It is also notable that 
outcome data in a non-transplant specialist programme identified non-treatment with 
Azathioprine as a risk factor for progression to liver transplantation and liver-related 
death (HR 3.96), as well as all-cause mortality (HR 2.71) [8].  
 
Once achieved, biochemical remission can be maintained in the majority of patients 
with Prednisolone (gradually tapered to ~7.5-12.5mg/day), alongside Azathioprine 1-
2mg/kg/day. Higher dosages of Azathioprine (2mg/kg/day) may be needed when 
bridging to monotherapy, but this can be tailored to individual response. At higher 
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doses the risks of Azathioprine induced malignancy, especially in those over the age 
of 60, is an important consideration as highlighted by recent IBD literature. 
Thiopurine metabolite monitoring may have a role, but at present is usually limited to 
those in need of intensified treatment or where drug adherence is a concern [24].  
 
Whilst disease control can be achieved and sustained with a very small dose of 
corticosteroids, Prednisolone monotherapy has a limited role in maintaining 
remission. This approach is largely reserved for patients intolerant or refractory to 
immunomodulators, and for patients whom the avoidance of side effects from therapy 
such as Azathioprine may be of greater concern. In such situations it can occasionally 
be reasonable to use monotherapy with corticosteroids from the very outset with no 
planned addition of Azathioprine or equivalent. In the authors’ experience, this is 
often in the quite elderly patient, for whom excellent response to treatment can be 
sustained with very modest Prednisolone dosages (e.g. 2.5mg or 5mg per day). The 
efficacy and long-term safety of Budesonide maintenance monotherapy is also 
currently unknown, albeit anecdotally, can be considered in selected patients. 
 
Duration of therapy  
Although there is no consensus on optimal duration, current guidelines recommend 
treatment be continued for long enough to make histological resolution ‘likely’ [6]. 
Twelve months is probably inadequate given the relatively low histological remission 
rate; but for non-cirrhotic patients with type-I AIH, who are SLA negative, a finite 
duration with corticosteroids for 18-24 months and Azathioprine for 3-5 years, prior 
to a single trial off therapy provided transaminases and IgG have remained normal 
during this time, is reasonable to discuss with patients.  
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Tapering of corticosteroids without repeat liver biopsy, provided full biochemical and 
immunological remission has been attained, is based on data showing correlation with 
a lower hepatic activity index (HAI<4) in 18/22 patients prospectively followed up 
over a median of 5.6 years [18]. However, ~45% of patients who maintain a serum 
ALT and globulin value within the normal range will have persisting histological 
activity (HAI >4) [10]. This is associated with heightened need for liver 
transplantation and increased all-cause mortality (HR 3.1). However, it is not known 
whether treatment intensification is beneficial. 
 
Between 41-55% of patients eventually develop an episode of relapse (an increase in 
serum ALT >3xULN + an increase in serum IgG >20g/L) after attaining remission, 
despite ongoing therapy [8,9]. The odds appears to be lower in patients of older 
presenting age (>18 years; odds ratio [OR]: 0.29), and heightened in those who are 
HLADRB1*04:01 positive (0R: 2.3). Disease relapse and loss of remission (increase 
in serum ALT >ULN) are a particular issue after tapering or cessation of treatment. 
The Dutch AIH working Group have reported a relapse rate of 59%, 81% and 88% at 
1, 3 and 5 years, respectively, even when treatment was tapered and/or discontinued 
after clinical and biochemical remission had been sustained for >2 years [25]. The 
incidence of relapse appeared greater when tapering of medication was trialled in 
younger patients (age <45 years) and those still requiring combination therapy 
(overall rate of relapse or loss of response: 59% vs. 19% in Prednisolone/Azathioprine 
combination and Azathioprine monotherapy arms, respectively). Azathioprine 
monotherapy is as effective at maintaining remission as dual therapy with 
Prednisolone/Azathioprine, and also associated with fewer side effects [26]. It is 
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therefore common practice to attempt use of Azathioprine monotherapy in patients 
who have attained sustained remission (approximately 18 – 24 months) without prior 
history of relapse.  
 
Relapse is more likely to occur on treatment withdrawal in the event persistent 
histological inflammatory activity is present (HAI >3). Thus it has been advised that 
biopsy be performed routinely for all patients prior to trialling cessation of therapy 
[7]. However, data from a small European cohort showed that approximately 50% of 
patients still require re-treatment despite having an absence of inflammatory activity 
(HAI<3). Further insights into the predictive components of liver histology stem from 
a study in the United States (n=88), which indicated persistence of plasma cells in the 
portal tracts as the sole critical factor in determining risk of relapse, whilst median 
HAI was no different between relapsers vs. non-relapsers [27].  
 
Whilst it is a valid perspective to biopsy prior to treatment withdrawal, a paradigm 
that is more selective in the use of liver biopsy is equally reasonable, with the 
important practice point for ALL patients who stop therapy to be monitored closely 
for relapse. The nature of clinical practice is also relevant: clinicians managing large 
cohorts of patients with AIH may be better placed to identify heterogeneity in disease 
course such that liver biopsy, for example prior to treatment withdrawal, is less 
frequently of clinical utility. Whereas those with broader clinical programmes in 
whom AIH is much less frequent, may find the information added by an additional 
measure of disease activity, in particular histology, helpful. 
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Populations with added clinical challenges 
Development of PSC and relevance to clinical practice 
Whilst a single diagnostic test does not exist for AIH [1], a series of weighted criteria 
devised by the International AIH Group (IAIHG) can facilitate some uniformity in 
diagnosis. At the time of development, the principled intent was to ensure 
comparability of patient populations in clinical research. Therefore the IAIHG scoring 
system should not be applied as a discriminative diagnostic index implying that 
manifestations of AIH are somehow unique, and can be siloed within disease-specific 
borders. Manifestations that are also common to PSC and primary biliary cholangitis 
(PBC), include interface hepatitis, presence of autoantibodies and elevated serum 
immunoglobulin concentrations [28]. Overlap ‘features’ be they biochemical, 
serological, histological or radiological, are hence frequently shared across all three 
autoimmune liver diseases, with some less categorical and objective than others.  
 
Accepting these caveats, the IAIHG propose that “although patients may have 
overlapping features across the spectrum of autoimmune liver injury, individual cases 
should be categorised according to the predominant disease entity; and that the 
IAIHG scoring system should not be used to diagnose distinct subgroups of patients 
[29].” An appraisal of disease phenotype must be performed longitudinally rather than 
at a single point in time, which is particularly relevant for those of younger presenting 
age. Of note, ~50% of paediatric patients with typical biochemical and immunological 
features of AIH can manifest a cholangiographic phenotype indicative of sclerosing 
cholangitis [30]. This group enter biochemical remission less often than those with a 
‘pure’ AIH phenotype (83% vs. 100%), and experience relapses characterised by 
elevations in serum gamma glutamyl transpeptidase (GT) [30]. Cholangiographic 
  
 18 
abnormalities also evolve in 10-24% of adult AIH patients [31,32], and as expected, 
more predominant in patients of younger presenting age (24 vs. 39 yrs. in one study). 
The prevalence of features of AIH within the International PSC Study Group 
([IPSCSG; n=7,121), was approximately 7% (n=470) of PSC patients [33]. However, 
with no codified diagnostic approach, the proportion of overlap cases relative to PSC 
varied widely between contributing centres, being heavily influenced by location 
(Australia, 2%; North America, 3%; Western Europe, 6%; Northern Europe, 7%; 
Southern Europe, 8%; Central Europe, 10%).  
 
Patterns of liver biochemistry in PSC are influenced by age at presentation, and a 
‘hepatitic’ laboratory profile does not automatically equal AIH overlap. In our 
programme we have shown a negative correlation between presenting age vs. serum 
ALP (Spearman’s rho 0.247; p=0.009) and vs. the serum AST:ALP ratio in PSC 
specifically (Spearman’s rho: -0.253; p = 0.007) [34]. Moreover, >50% of PSC 
patients presenting between 18 to 25 years of age displayed a serum AST value 
>2xULN; vs. <30% in groups aged >25-43 years, 43-55 years and >55 years (n=112 
overall; p=0.03). 
 
The development of PSC must be considered in AIH patients who are poorly 
responsive to immunosuppressive therapy [35,36], however as the radiological 
hallmark of PSC (beading and stricturing of the biliary tree on cholangiography) is a 
late manifestation, the exact interval between onset of AIH and PSC is difficult to 
determine. Key to practice is the fact that no significant differences in transplant-free 
survival were seen in the IPSCSG cohort which compared adult patients having 
classical PSC vs. those with PSC/AIH (incidence rate [IR] of liver 
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transplant/mortality: 5.62 vs. 4.70 per 100 pt.-yrs, p=n.s. [33]). This observation was 
mirrored in a multi-centre paediatric study of 781 children with PSC (5-year event-
free survival: 88% vs. 90% [37]). 
 
As AIH evolves to PSC clinically, typical histological features of AIH such as portal 
inflammation and interface hepatitis tend to subside, likely reflecting successful 
therapeutic suppression of inflammation, and features of chronic biliary disease 
become more prominent. The changes seen include bile duct loss, ductular reaction 
often associated with a ‘biliary pattern’ of interface activity and fibrosis, and features 
of chronic cholestasis including the accumulation of copper and copper-associated 
protein in periportal hepatocytes. Classical ‘onion-skin’ foci of periductal fibrosis 
mainly involve medium sized ducts and are thus seen infrequently in needle biopsy 
specimens.  Liver biopsy is still helpful in this setting, both in identifying the presence 
of ongoing inflammation, and in detecting features of chronic biliary disease, which 
may prompt additional investigations and provoke alternative management strategies 
(Figure 1E). 
 
A longitudinal approach to care must be adopted when managing autoimmune liver 
disease, focusing on clarity and accuracy in disease definition and rationale for 
treatment. This is particularly relevant when immunosuppression is offered to patients 
with PSC and overlapping AIH features; an intervention not supported by evidence of 
benefit. Conventional remission criteria for AIH cannot be applied to patients with 
PSC, who may develop progressive liver disease irrespective of whether they 
normalise AST, ALT and/or immunological parameters [38].  
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Phenotypic differences between adult-onset AIH type-I and type-II 
Attempts to sub-classify AIH based on serological phenotypes are frequently 
described, and the nature of autoantibodies can fluctuate before and after 
immunosuppressive therapy [39]. Approximately 65% of all patients will test positive 
for ANA and/or ASMA, which although non-disease specific are considered 
representative of Type-I AIH [40]. By contrast, anti-LKM-1 and anti liver cytosol 
(LC)-1 antibodies typify type-II disease. Across some settings, the latter accounts for 
~25% of AIH in children, and importantly, liver cirrhosis may already be established 
in 60% of at time of diagnosis. Early reports from the 1980s also suggested that this 
group of children more often present with fulminant hepatic failure than 
contemporaries with type-I AIH.  
 
Seropositivity against soluble liver antigen / liver pancreas antigen (anti-SLA/LP) is 
found in 22% of AIH patients [9], mostly in type-I disease. Indeed, ~90% of anti-
SLA/LP cases will also test positive for ANA and or ASMA, whereas coexistence 
with anti-LKM is rare. Anti-SLA/LP positivity may characterise a high-risk group for 
disease progression (HR for liver transplantation / death: 4.25 [9]), although this 
observation needs validation [39].  
 
Type-I AIH contributes ~90% of adult cases, with an average ‘quoted’ diagnosis age 
between 36-56 years, supporting the concept of two patterns of age related 
presentation [8,25]. By contrast, frequently fewer (2-10%) adult cases are contributed 
to by type-II AIH, although treatment paradigms do not tend to differentiate between 
serological phenotypes [9,41]. Nevertheless, therapeutic failures defined as the 
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presence of clinical/biochemical deterioration despite medication, appear to be less 
common in ANA-positive vs. negative patients (7% vs. 24%, p=0.016 [39]).  
 
The UK multi-centre audit confirmed Type 2 disease as associated more commonly 
with liver cirrhosis at diagnosis (47% vs. 25%; p=0.04) [41]. This is in contrast to an 
Italian group, who found no differences on comparing age- and sex-matched cohorts 
with regard to the frequency of cirrhotic presentations (12% vs. 19%, p=0.456), 
proportion attaining complete treatment response (50% vs. 60%, p=0.464), null 
responders (12.5% vs. 15%, p=0.788) and the number who relapse (81% vs. 78%, 
p=0.961) [42,43]. The nature of IgG elevation may also differ in adults, and be 
misleading as to severity of disease and it’s monitoring. Indeed, in our programme 
serum IgG values rarely become elevated in adult-onset LKM-1 positive AIH, even at 
the peak of hepatitis activity (Table 2).  
 
Pregnancy  
Pregnancy and AIH is another important area for discussion, and post-partum disease 
flares can be significant irrespective of AIH subtype, occurring in 25-30% of 
pregnancies. Disease flares are linked to poor disease control in the year prior to 
pregnancy, an absence of therapy whilst pregnant, and a significantly increased risk of 
hepatic decompensation and increased need for neonatal admission to special care 
baby units [44]. It is therefore critical that immunosuppression be continued during 
pregnancy and into the post-partum period, during which more active disease can be 
anticipated, and intensified monitoring and intervention offered as appropriate.  
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How is second-line therapy applied in clinical practice? 
Defining treatment failure 
Poor adherence is the first consideration during incidents of therapeutic failure, 
although deviation from the expected clinical course also warrants re-evaluation of 
diagnosis, exclusion of sclerosing cholangitis, and potentially drug malabsorption 
from poorly-controlled coeliac disease [21,28]. Assuming adherence and a correct 
diagnosis, patients who do not show clinical or laboratory improvement within 6 
months of starting 1st line therapy (10-15%) are deemed unresponsive, whereas those 
who deteriorate by any clinical or laboratory parameter despite compliance (~9%) are 
considered treatment failures. Of concern, failure to normalise serum ALT within 6-
12 months of presentation is associated with an >5-fold increased risk of liver-related 
death or transplantation [8,16] and such situations justify the reinstitution of 
Prednisolone (variable dose depending on clinical setting) alone or in conjunction 
with Azathioprine (2mg/kg/day). High dose corticosteroids, if chosen, are maintained 
for at least 1 month. Thereafter, the corticosteroid dose may be reduced according to 
clinical response.  
 
Continued deterioration despite the above measures may be an indication for 
alternative therapies, but obtaining histological evidence to confirm ongoing 
inflammatory disease is advised to ensure accurate diagnosis. This can help stratify 
treatment decisions, wherein the threshold to trial salvage therapies or triage to liver 
transplant assessment may be guided by the acuteness and severity of injury in the 
correct clinical context. Mostly, however, alternative therapies are needed because of 
drug intolerability (side-effects or complications) rather than corticosteroid-
dependency or non-response to primary therapy. Whilst the goals of treatment remain 
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unchanged, irrespective of the therapeutic paradigm selected, there are no randomised 
controlled trials to back any of the potential second-line treatments used in clinical 
practice.  
 
Optimising thiopurine delivery  
6-mercaptopurine (6-MP) has recently been proposed as an alternative therapeutic 
option for Azathioprine intolerance, although evidence for its efficacy in non-
responders is lacking. In a study of 20 patients with Azathioprine intolerance, 75% 
exhibited biochemical response to 6-MP; 8 having complete remission and 7 a partial 
improvement in liver biochemistry. The remaining 5 patients ceased 6-MP therapy in 
view of ongoing intolerance to thiopurines [45]. 
 
Elevated concentrations of the metabolite 6-methylmercaptopurine (MMPN) have 
been associated with the development of hepatotoxicity and therapeutic drug failure, 
particularly when coexistent with lower levels of 6-TGN. Co-administration of 
allopurinol alongside ‘low-dose’ thiopurines has been shown to redirect metabolism 
in one small study, with patients having prior dose-limiting intolerance (n=3), non-
response (n=3) or loss of response to standard thiopurine treatment [1]. All 8 patients 
normalised serum ALT within 1 month, in line with reduction in red blood cell 6-
MMP concentrations. Although limited by size, these findings are encouraging and 
require long-term validation in a larger, more homogeneous cohort of AIH patients.  
 
Mycophenolate Mofetil  
Mycophenolate Mofetil (MMF) is perhaps the most well-studied therapeutic 
alternative to Azathioprine; and although unlicensed, is accepted as second-line 
  
 24 
treatment by most [46,47]. Collectively, data surrounding MMF indicates use as a 
possible alternative for maintaining remission, largely reserved for instances when 
patients are intolerant of Azathioprine as opposed to non-responders. However, 
approximately 10-37% of patients discontinue MMF in view of adverse events-
particularly sepsis [47,48]. Of further, practical concern is its reported teratogenicity, 
which precludes use in women planning pregnancy (and raises concerns for men as 
well, which are unresolved).  
 
In the largest multi-centre cohort to date (n=121; dosage 0.5 to 2.0 g/day), the rate of 
complete response (normal liver biochemistry and serum IgG values) was 57% for 
patients with Azathioprine intolerance vs. 34% in those with prior non-response [2]. 
Of note, the rate of liver transplantation / liver-related mortality exceeded 10% at 5 
years for MMF-treated patients, considerably greater than that evident in 
predominantly Azathioprine-treated cohorts [8,9]. Mycophenolate has also been 
detailed as first-line therapy by a group from Greece (n=109; dosage 500mg/day), and 
led to biochemical and immunological remission (together with Prednisolone) in 72% 
of treated patients within the first 18 months [48]. However, the comparator group of 
patients, who received more conventional treatment with Azathioprine and 
Prednisolone, displayed a much lower rate of complete response (46%) than shown by 
other reports. Our practice when using MMF is to largely aim for a dose of 1g bid, but 
higher (up to 3g daily) and lower (e.g. 500mg bid) doses can be appropriate in 
selected patients, based for example on body mass and/or disease activity. 
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Tacrolimus 
Calcineurin inhibitors have been shown to be beneficial in inducing and maintaining 
biochemical remission in small numbers of patients, mostly children. Support of 
therapeutic efficacy in adults is lent by a multi-centre in which 58/80 patients who 
were either non-responsive or intolerant to Azathioprine achieved complete 
biochemical response [2]. Notably, the rate of complete biochemical and 
immunological remission in prior Azathioprine non-responders was significantly 
greater with Tacrolimus (1-8mg/day) vs. MMF second line therapy (0.5-2g/day); 57% 
vs. 34%, p=0.029), respectively, although significant side effects led to drug 
withdrawal in 10% of patients, with high mortality rates observed in both groups 
(10% vs. 13% over 5 years). Target drug trough values were not specified, although a 
mean level of 6 ng/mL has been cited elsewhere [7].  In our practice the target trough 
level is related to the relative indication- in those for whom Tacrolimus is used to 
adjunct to existing dual therapy the authors usually advise trough levels of 3-5ng/mL; 
in those for whom Tacrolimus represents the mainstay of immunosuppression, trough 
levels of 5-7ng/mL are more often advocated. 
 
Biologics  
The patient presented in our vignette was able to attain remission although this could 
not be sustained via conventional means following a period of non-adherence. Despite 
best efforts with thiopurine therapy she required consistently high dosages of 
corticosteroids and failed second-line treatment with MMF. Few salvage therapies 
have been identified for AIH that is recalcitrant to conventional treatment. One 
retrospective series has reported success in using infliximab [49], albeit with concern 
over side-effects. Anti-TNFhas also been associated with hepatotoxicity in a 
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number of case series, albeit not necessarily reflective of a classical immune-mediated 
process. Rituximab is a chimeric monoclonal antibody directed against the CD20 
antigen on the surface of normal and malignant B-cells. To date, there have been 
several small case series describing the rituximab experience in AIH, and collectively 
the data is promising, and supportive of the need for prospective trials. B-cell 
activating factor (BAFF), which belongs to the tumour necrosis factor superfamily, is 
also well known for its role in the survival and maturation of B-cells, and elevated in 
the serum of patients with AIH where values correlates with serum transaminase 
activity. An anti-BAFF receptor antibody therapy will be tested in a multicentre trial 
in AIH (NCT03217422). 
 
Conclusion 
When managing patients with AIH, a long-term longitudinal approach to care must be 
applied. This must focus on confidence and clarity in diagnosis, individualised 
assessment of risk, and clinician-patient partnership in establishing the rationale for 
(often lifelong) treatment in the context of clear clinical benefits in the short- and 
long-term, but equally adverse treatment related risks. Complete remission is an 
attainable and appropriate target for most patients with an associated improved 
transplant-free survival. However inadequate disease control, for many reasons 
(disease severity, treatment side-effects, adherence) alongside poor recognition of the 
quality-of-life impairment, remains high. Equally, care continues to address chronic 
suppression of persistent immune activity in contrast to offering patients ‘cure’. 
Didactic indications for immunosuppression remain inadequately defined for 
subgroups such as those manifesting asymptomatic and mild disease, ‘burned-out’ 
cirrhosis, or those with overlap biliary presentations. Those presenting at a young age 
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have added practical challenges, including often adherence to therapy, severity of 
disease associated with LKM/anti-LC-positive disease, fertility/pregnancy concerns, 
and a much greater reality of clinically meaningful biliary overlap evolution over 
time. There remains a need for long-term large and representative clinical cohort 
studies as these will add value in AIH, providing contemporaneous recognition of 
clinical and individual burden of disease. Such studies have the potential to help 
justify the evolution of our currently limited treatment paradigms, to approaches that 
better reflect the state-of-the-art management of more common autoimmune diseases, 
such as rheumatoid arthritis or ulcerative colitis. 
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Table 1: Holistic care of the patient with autoimmune hepatitis 
Domain Comments 
Timely and individualised therapy - Precise regimens vary between guidelines, and in practice must be 
tailored to underlying inflammatory activity, disease severity and patient 
tolerability: 
 
- Elderly patients: may respond to lower low dosages of corticosteroids 
(10-20mg Prednisolone, or equivalent) to enter remission. 
 
- Pregnancy: spontaneous disease remission common, but disease relapse 
often manifests in the post-partum period particularly for those not on 
therapy during pregnancy (50% vs. 26% for women on 
immunosuppression). 
 
- Acute onset, fulminant presentations: less favourable response to 
corticosteroids (~50%) and should be managed in the context of 
expectant transplantation (60% needing transplantation; 20% mortality). 
 
- Failure to induce remission, or loss of prior response in the young patient 
must prompt investigation of ‘evolving’ sclerosing cholangitis. 
Maintaining adherence to treatment - Stratified, personalised approach, best attained through good continuity 
of care. 
 
- Specialist nurses play a vital role in managing chronic disease [50]. 
Optimised care provision through evaluating, monitoring and education; 
in addition to facilitating an individualised approach to treatment and 
follow up that is of greatest efficacy and lowest burden to patients. 
 
- Monitoring of thiopurine metabolites facilitates tailoring of therapy and 
monitoring drug compliance. 
Symptomatology and extrahepatic manifestations - Protective measures for all those on long-term corticosteroids. Consider 
Budesonide as first line in non-cirrhotic patients with features of 
metabolic syndrome and/or diabetes mellitus. 
 
- Side effects of thiopurines can lead to treatment discontinuation.in 5% to 
19% of patients. Improved tolerability can be achieved by starting with 
lower dosages and titratng according to thiopurine metabolite levels. 
 
- Fatigue and arthralgia are recognised symptoms, which may correlate 
with underlying disease activity.  
 
- Pruritus is uncommon compared to that found in chronic cholestatic 
liver diseases, but may herald an ‘evolving’ sclerosing cholangitis. 
Surveillance of complications - Bone density measurements at the onset of corticosteroid therapy. 
 
- Hepatocellular carcinoma screening for patients with established liver 
cirrhosis. 
 
- Check for gastroesophageal varices according to Baveno guidelines. 
Side effects of therapy - Monitoring of blood glucose and bone density recommended at initiation 
of systemic corticosteroid therapy. Although precise intervals for 
surveillance are ill defined, we recommend HbA1c be monitored 6-12 
monthly, and bone densitometry 3-5 yearly in the event Prednisolone 
therapy continues >10 mg/day. Supplementation of vitamin D and 
adequate calcium intake are commonly advised and added bone-specific 
therapy according to local practice, taking account of patient-specific 
(age and sex) and disease-specific (activity and severity) factors. 
 
- Monitoring strategy under thiopurine therapy is largely extrapolated 
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from data in inflammatory bowel disease (IBD). Checking thiopurine 
methyltransferase (TPMT) is logical prior to commencement of therapy, 
and dosing adjusted accordingly, albeit all patients must have 
monitoring on therapy [54].  
 
- Checking full blood count and renal function is recommended at for 
example weeks 2, 4, 8 and 12, and then 3-monthly thereafter for patients 
under therapy with thiopurines, mycophenolate and tacrolimus; 
principally to screen for cytopenia and cell dyscrasias. 
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Table 2: Presenting features of adult-onset anti-LKM-1 positive autoimmune hepatitis* 
Year of 
diagnosis 
Sex Diagnosis age 
(yrs.) 
Presentation Peak serum ALT  
(IU/L) 
Steroid-responsive (Y/N) Peak serum IgG 
(g/L) ** 
2001 Male 21 Acute hepatitis with jaundice 1705 N 13.10 
2003 Female 22 Post-partum jaundice 1003 Y 32.77 
2004 Female 16 Fatigue 885 Y 15.68 
2005 Female 28 Fulminant liver failure 565 Y 14.61 
2006 Female 18 Fulminant liver failure 1102 
N/A; urgent liver 
transplant 
18.01 
2007 Female 24 Post-partum jaundice 780 Y 12.22 
2010 Female 19 Acute hepatitis with jaundice 108 N 14.25 
2011 Male 33 Abdominal pain 250 Y 10.63 
2011 Female 18 Acute hepatitis with jaundice 1031 Y 11.61 
2012 Female 27 Acute hepatitis with jaundice 108 Y 14.91 
2013 Female 24 Post-partum jaundice 698 Y 14.16 
2013 Female 33 Decompensated liver cirrhosis 115 N 15.99 
*Incident cases of anti-LKM-1 positive autoimmune hepatitis seen in the Birmingham liver clinic since the year 2000. Only adult onset (diagnosed >16 yrs. of 
age) episodes are shown. All patients underwent confirmatory liver biopsy. 
** Upper limit of normal for IgG: 16 g/L 
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Figure 1: Clinical course and patterns of injury in autoimmune hepatitis 
[A] Timeline graph of laboratory parameters from the case is shown during the patient’s initial 
presentation and phase of treatment, with black arrowheads indicating the start date of oral 
Prednisolone at 20mg once daily, and white arrowhead the introduction of Azathioprine. [B] 
Timeline graph of laboratory parameters from the same patient is shown, who represented after a 
period of non-attendance to clinic. Black arrowhead indicates re-initiation of Prednisolone and white 
arrowhead Azathioprine. Single and double asterisks indicate the duration of MMF and Tacrolimus 
therapy (without Azathioprine), respectively, and black arrow the first infusion of Rituximab. [C] 
Representative images showing typical features of chronic AIH. From left to right: (i) a portal tract 
containing a dense lymphoplasmacytic infiltrate associated with moderate interface hepatitis; 
(ii) interface hepatitis is associated with periportal hepatocyte rosetting and focal 
emperipolesis; (iii) there is extensive lobular dissection by delicate strands of fibrous tissue, 
which surround small clusters of hepatocytes forming rosettes (Haematoxylin van-Gieson 
stain). [D] Representative sections showing changes seen in a case of severe AIH with an acute 
presentation. From left to right: (i) a plasma cell rich portal inflammatory infiltrate; (ii) lobular 
hepatitis with prominent plasma cell rich centrilobular inflammation associated with bridging 
necrosis; and (iii) severe lobular hepatitis with almost pan-acinar necrosis and only occasional 
small groups of surviving hepatocytes. [E] Evolution of histological changes from a patient having 
initial diagnosis of AIH that progressed to a PSC predominant phenotype over a three year period, 
necessitating transplantation due to chronic liver failure and recurrent cholangitis. (i) The first biopsy 
obtained at diagnosis shows features of acute AIH with prominent lobular inflammation. There is 
diffuse spotty lobular inflammation associated with hepatocyte ballooning and lobular disarray. The 
portal tract also contains a moderately dense infiltrate of inflammatory cells. (ii) The second biopsy 
obtained (750 days) illustrates progression to more typical features of chronic hepatitis with 
predominant portal inflammation. The portal tract contains a moderately dense infiltrate of 
mononuclear inflammatory cells. There is focal, mild interface activity but no significant fibrosis is 
present. Lobular inflammation has resolved. (iii) The hepatectomy specimen obtained at 
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transplantation (2,982 days) shows a fibro-obliterative duct lesion typical of PSC. A large portal tract 
contains a nodule of fibrous tissue related to an obliterated bile duct, and peribiliary glands are visible 
in the bottom right. 
AIH, Autoimmune hepatitis; MMF, Mycophenolate Mofetil; PSC, Primary sclerosing cholangitis 
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Figure 2: Practice tips for managing autoimmune hepatitis 
Accurate diagnosis of AIH relies on the collective interpretation of laboratory indices 
together with liver biopsy review by a dedicated hepatopathologist. Recognising that 
a characteristic biologic feature of classical AIH is its response to 
immunosuppression, this reflects something that always needs to be looked for. The 
diversity in currently proposed treatment algorithms has resulted in wide variations of 
clinical practice, although corticosteroids remain essential to induce remission. 
Timely immunosuppression is a proven lifesaving intervention, although a lack of 
consensus on dosage suggests there is need for more precise markers of disease 
severity. In any event, a most critical element of effective care delivery centres on 
securing adherence to therapy, and individualising treatment regimens according to 
symptoms and tolerability. Uncertainty regarding diagnosis, failure of a patient to 
attain (or sustain) remission, and acute-severe presentations or incidents of hepatic 
decompensation are absolute indications for specialist centre referral, given the very 
real risk of rapid and progressive clinical deterioration and potential need for salvage 
therapy / transplantation.  
AIH, Autoimmune hepatitis 
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